Villejuif

• A Phase 1, Open-Label Dose Escalation and Expansion study of SNV1521 in Participants with Advanced Solid Tumors Recruiting
  2025-520557-36-00 1 2025-07-24 Advanced Solid Tumors
• A study to determine how safe MB-CART2019.1 is and how well it works in children and adolescents with B cell neoplasms Recruiting
  2023-506348-17-00 4 2025-07-22 Relapsed/refractory (r/r) mature B cell neoplasms who have relapsed af
• A study to test the safety and efficacy of EP102 in patients with advanced solid tumours Recruiting
  2025-521305-40-00 1 2025-07-22 Participants with Advanced Solid Tumors
• A Study to Learn About the Study Medicine Called Sigvotatug Vedotin in People with Locally Advanced, Unresectable, or Metastatic Non-Small C … Recruiting
  2024-517968-36-00 5 2025-07-08 non-small cell lung cancer
• A Phase 3, Randomized, Open-Label Study of Axatilimab Versus Best Available Therapy in Participants With Chronic Graft-Versus-Host Disease A … Recruiting
  2024-518973-32-00 5 2025-07-03 Chronic Graft-Versus-Host Disease
• Phase 2, Multicenter, Open label, Platform Study investigating Tarlatamab (AMG 757) in patients with Metastatic/Locally Advanced Small-Cell … Recruiting
  2024-515847-47-00 4 2025-06-24 Metastaic small cell lung cancer (SCLC) and other poorly differentitat
• Phase 1b/2 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Pancreatic Cancer (Substudy PDAC) Recruiting
  2024-517819-74-00 9 2025-06-02 Pancreatic Ductal Adenocarcinoma
• First trial in humans testing the safety and efficacy of IMGN151 in women with recurrent gynaecological cancers Recruiting
  2023-506842-22-00 7 2025-05-19 Recurrent endometrial cancer, recurrent epithelial ovarian, fallopian
• Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients with FLT3-ITD Negative AML Recruiting
  2023-507936-20-00 5 2025-05-05 Acute myeloid leukemia
• A Study to see How Well and How Safely Different Treatments Work in a Group of Patients with Non-Small Cell Lung Cancer, Chosen Based on the … Recruiting
  2024-511239-91-00 4 2025-05-05 Resectable Stage I-III Non-Small Cell Lung Cancer (NSCLC)
• SUPRAME - ACTengine® IMA203 vs. investigator’s choice of treatment in previously treated, unresectable or metastatic cutaneous melanoma Recruiting
  2024-517062-42-00 5 2025-05-02 melanoma, cutaneous malignant
• An Open-Label, Phase 1 Study of the CTPS1 Inhibitor STP938 in Adult Subjects with Advanced Solid Tumors, with a Safety Expansion in Advance … Recruiting
  2024-512375-12-00 3 2025-04-18 Solid tumors and ovarian cancer
• A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK-2870-022) Recruiting
  2023-508015-23-00 5 2025-04-11 Ovarian cancer recurrent
• Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C … Recruiting
  2024-515445-42-00 5 2025-03-24 Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
• A Study to Assess Livmoniplimab in Combination with Budigalimab Versus Chemotherapy in Adult Participants with Metastatic Urothelial Carcino … Recruiting
  2024-515506-11-00 4 2025-03-24 Urothelial Carcinoma
• A Randomized, Double-Blind, Placebo-Controlled, MultiRegional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemal … Recruiting
  2023-507097-41-01 5 2025-03-20 Patients with limited-stage small cell lung cancer (LS-SCLC) without
• KISIMA-02 vaccine-based immunotherapy for patients with pancreatic cancer Recruiting
  2022-501854-12-01 1 2025-02-05 G12D/G12V Pancreatic Ductal Adenocarcinoma
• A study to investigate efficacy and safety of INT230-6 compared with US standard of care in participants aged ≥ 18 years old with metastatic … Recruiting
  2024-512423-36-00 5 2024-11-20 Leiomyosarcoma (non-uterine)
• NEOADJUVANT ATEZOLIZUMAB AND ADJUVANT ATEZOLIZUMAB + BEVACIZUMAB IN COMBINATION WITH PERCUTANEOUS RADIOFREQUENCY ABLATION OF SMALL HCC: A MU … Recruiting
  2024-519113-59-00 4 2024-11-20 Hepatocellular carcinoma
• A study to test the safety and efficacy of a new drug, AZD3470, in patients with advanced solid tumours. Recruiting
  2023-506757-38-00 1 2024-11-14 Advanced/metastatic solid tumors that are MTAP deficient.
• Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART) Recruiting
  2024-513219-29-00 5 2024-10-21 Renal Cell Carcinoma
• A phase 3 study to look at the effects of 2 treatments used together (ficlatuzumab and cetuximab) on the overall survival of adults with a c … Recruiting
  2023-505606-42-00 5 2024-10-15 Head and Neck Squamous Cell Carcinoma (HNSCC)
• A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better than Anti-PD1 Alone in Adult Participants with Resectable Stage 3 or 4 … Recruiting
  2022-502825-17-00 4 2024-10-07 Melanoma
• A RANDOMIZED, OPEN-LABEL PHASE 3 STUDY IN PATIENTS WITH PREVIOUSLY TREATED UNRESECTABLE OR METASTATIC NRAS MUTANT CUTANEOUS MELANOMA COMPARI … Recruiting
  2024-511404-17-00 5 2024-10-07 Unresectable or metastatic NRAS mutant cutaneous melanoma

Showing 97–120 of 978 trials